• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

癌症研究的最新进展:对新疗法的期望。

Recent developments in cancer research: Expectations for a new remedy.

作者信息

Ando Koji, Hu Qingjiang, Kasagi Yuta, Oki Eiji, Mori Masaki

机构信息

Department of Surgery and Science Kyushu University Fukuoka Japan.

出版信息

Ann Gastroenterol Surg. 2021 Feb 15;5(4):419-426. doi: 10.1002/ags3.12440. eCollection 2021 Jul.

DOI:10.1002/ags3.12440
PMID:34337290
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8316733/
Abstract

Cancer research has made remarkable progress and new discoveries are beginning to be made. For example, the discovery of immune checkpoint inhibition mechanisms in cancer cells has led to the development of immune checkpoint inhibitors that have benefited many cancer patients. In this review, we will introduce and describe the latest novel areas of cancer research: exosomes, microbiome, immunotherapy. and organoids. Exosomes research will lead to further understanding of the mechanisms governing cancer proliferation, invasion, and metastasis, as well as the development of cancer detection and therapeutic methods. Microbiome are important in understanding the disease. Immunotherapy is the fourth treatment in cancer therapy. Organoid biology will further develop with a goal of translating the research into personalized therapy. These research areas may result in the creation of new cancer treatments in the future.

摘要

癌症研究取得了显著进展,新的发现也不断涌现。例如,癌细胞中免疫检查点抑制机制的发现促使了免疫检查点抑制剂的研发,使许多癌症患者受益。在本综述中,我们将介绍并描述癌症研究的最新前沿领域:外泌体、微生物组、免疫疗法和类器官。外泌体研究将有助于进一步了解癌症增殖、侵袭和转移的机制,以及癌症检测和治疗方法的开发。微生物组对于理解疾病很重要。免疫疗法是癌症治疗中的第四种治疗方式。类器官生物学将进一步发展,目标是将研究转化为个性化治疗。这些研究领域未来可能会催生新的癌症治疗方法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c685/8316733/fe8b5554f03e/AGS3-5-419-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c685/8316733/fe8b5554f03e/AGS3-5-419-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c685/8316733/fe8b5554f03e/AGS3-5-419-g002.jpg

相似文献

1
Recent developments in cancer research: Expectations for a new remedy.癌症研究的最新进展:对新疗法的期望。
Ann Gastroenterol Surg. 2021 Feb 15;5(4):419-426. doi: 10.1002/ags3.12440. eCollection 2021 Jul.
2
Tumor organoids: synergistic applications, current challenges, and future prospects in cancer therapy.肿瘤类器官:在癌症治疗中的协同应用、当前挑战与未来前景。
Cancer Commun (Lond). 2021 Dec;41(12):1331-1353. doi: 10.1002/cac2.12224. Epub 2021 Oct 29.
3
Emerging organoid-immune co-culture models for cancer research: from oncoimmunology to personalized immunotherapies.新兴的类器官-免疫共培养模型在癌症研究中的应用:从肿瘤免疫学到个体化免疫治疗。
J Immunother Cancer. 2023 May;11(5). doi: 10.1136/jitc-2022-006290.
4
Towards the era of immune checkpoint inhibitors and personalized cancer immunotherapy.迈向免疫检查点抑制剂和个体化癌症免疫治疗的时代。
Immunol Med. 2021 Mar;44(1):10-15. doi: 10.1080/25785826.2020.1785654. Epub 2020 Jul 9.
5
Immunotherapy discovery on tumor organoid-on-a-chip platforms that recapitulate the tumor microenvironment.在能够重现肿瘤微环境的肿瘤类器官芯片平台上进行免疫疗法的发现。
Adv Drug Deliv Rev. 2022 Aug;187:114365. doi: 10.1016/j.addr.2022.114365. Epub 2022 Jun 3.
6
Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects.三阴性乳腺癌的免疫治疗:现存挑战与振奋前景。
Drug Resist Updat. 2017 May;32:1-15. doi: 10.1016/j.drup.2017.07.002. Epub 2017 Aug 19.
7
From a Patient Advocate's Perspective: Does Cancer Immunotherapy Represent a Paradigm Shift?从患者权益倡导者的角度来看:癌症免疫疗法是否代表了一种范式转变?
Curr Oncol Rep. 2018 Feb 7;20(1):8. doi: 10.1007/s11912-018-0662-5.
8
[Tracking Research Progress in the Modulatory Role of Gut Microbiome in Immune Checkpoint Inhibitors Applied in Cancer Treatment].[追踪肠道微生物群在癌症治疗中应用的免疫检查点抑制剂调节作用的研究进展]
Sichuan Da Xue Xue Bao Yi Xue Ban. 2021 Sep;52(5):735-739. doi: 10.12182/20210960501.
9
The Evolution of Cancer Immunotherapy.癌症免疫疗法的演变
Vaccines (Basel). 2021 Jun 8;9(6):614. doi: 10.3390/vaccines9060614.
10
Emerging Opportunities and Challenges in Cancer Immunotherapy.癌症免疫疗法中的新机遇与挑战
Clin Cancer Res. 2016 Apr 15;22(8):1845-55. doi: 10.1158/1078-0432.CCR-16-0049.

引用本文的文献

1
Cancer and Traditional Medicine: An Integrative Approach.癌症与传统医学:一种综合方法。
Pharmaceuticals (Basel). 2025 Apr 28;18(5):644. doi: 10.3390/ph18050644.
2
Significance of homologous recombinant deficiency as a biomarker for drug sensitivity in colorectal cancer.同源重组缺陷作为结直肠癌药物敏感性生物标志物的意义
Br J Cancer. 2025 Apr;132(6):533-542. doi: 10.1038/s41416-025-02950-5. Epub 2025 Feb 11.
3
Emerging Gene-editing nano-therapeutics for Cancer.新兴的用于癌症治疗的基因编辑纳米疗法

本文引用的文献

1
The model of cytokine release syndrome in CAR T-cell treatment for B-cell non-Hodgkin lymphoma.嵌合抗原受体 T 细胞治疗 B 细胞非霍奇金淋巴瘤中细胞因子释放综合征模型。
Signal Transduct Target Ther. 2020 Jul 29;5(1):134. doi: 10.1038/s41392-020-00256-x.
2
Exosomes Derived from Brain Metastatic Breast Cancer Cells Destroy the Blood-Brain Barrier by Carrying lncRNA GS1-600G8.5.脑转移乳腺癌细胞来源的外泌体通过携带 lncRNA GS1-600G8.5 破坏血脑屏障。
Biomed Res Int. 2020 Apr 6;2020:7461727. doi: 10.1155/2020/7461727. eCollection 2020.
3
IgA and the intestinal microbiota: the importance of being specific.
Heliyon. 2024 Oct 20;10(21):e39323. doi: 10.1016/j.heliyon.2024.e39323. eCollection 2024 Nov 15.
4
C-reactive protein kinetics as a predictive marker for long-term outcome of immune checkpoint inhibitors in oesophagogastric cancer.C反应蛋白动力学作为食管胃癌免疫检查点抑制剂长期疗效的预测标志物
BJC Rep. 2023 Aug 2;1(1):7. doi: 10.1038/s44276-023-00005-x.
5
Development and Feasibility Evaluation of Smart Cancer Care 2.0 Based on Patient-Reported Outcomes for Post-Discharge Management of Patients with Cancer.基于患者报告结局的癌症患者出院后管理的智慧癌症关爱 2.0 的开发和可行性评估。
Cancer Res Treat. 2024 Oct;56(4):1040-1049. doi: 10.4143/crt.2024.003. Epub 2024 Apr 9.
6
The effects of statin therapy on brain tumors, particularly glioma: a review.他汀类药物治疗对脑瘤(尤其是神经胶质瘤)的影响:综述。
Anticancer Drugs. 2023 Oct 1;34(9):985-994. doi: 10.1097/CAD.0000000000001533. Epub 2023 Jul 19.
7
Accum™ Technology: A Novel Conjugable Primer for Onco-Immunotherapy.Accum™ 技术:一种新型的用于癌症免疫治疗的偶联引物。
Molecules. 2022 Jun 13;27(12):3807. doi: 10.3390/molecules27123807.
8
Cancer Stem Cells (CSCs), Circulating Tumor Cells (CTCs) and Their Interplay with Cancer Associated Fibroblasts (CAFs): A New World of Targets and Treatments.癌症干细胞(CSCs)、循环肿瘤细胞(CTCs)及其与癌症相关成纤维细胞(CAFs)的相互作用:一个新的靶点与治疗领域。
Cancers (Basel). 2022 May 13;14(10):2408. doi: 10.3390/cancers14102408.
9
Lipid Droplets in Cancer: From Composition and Role to Imaging and Therapeutics.脂质滴在癌症中的作用:从组成、功能到成像和治疗。
Molecules. 2022 Feb 1;27(3):991. doi: 10.3390/molecules27030991.
IgA 与肠道微生物群:具体问题具体分析的重要性。
Mucosal Immunol. 2020 Jan;13(1):12-21. doi: 10.1038/s41385-019-0227-4. Epub 2019 Nov 18.
4
Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial.纳武利尤单抗对比化疗用于既往化疗后进展或不耐受的晚期食管鳞癌患者(ATTRACTION-3):一项多中心、随机、开放标签、III 期临床研究。
Lancet Oncol. 2019 Nov;20(11):1506-1517. doi: 10.1016/S1470-2045(19)30626-6. Epub 2019 Sep 30.
5
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.纳武利尤单抗联合伊匹木单抗治疗晚期黑色素瘤的 5 年生存数据
N Engl J Med. 2019 Oct 17;381(16):1535-1546. doi: 10.1056/NEJMoa1910836. Epub 2019 Sep 28.
6
Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer.纳武利尤单抗联合伊匹单抗治疗晚期非小细胞肺癌。
N Engl J Med. 2019 Nov 21;381(21):2020-2031. doi: 10.1056/NEJMoa1910231. Epub 2019 Sep 28.
7
Engineered triple inhibitory receptor resistance improves anti-tumor CAR-T cell performance via CD56.工程化三重抑制性受体抗性通过 CD56 提高抗肿瘤 CAR-T 细胞的疗效。
Nat Commun. 2019 Sep 11;10(1):4109. doi: 10.1038/s41467-019-11893-4.
8
Metagenomic and metabolomic analyses reveal distinct stage-specific phenotypes of the gut microbiota in colorectal cancer.宏基因组学和代谢组学分析揭示了结直肠癌肠道微生物群的不同阶段特异性表型。
Nat Med. 2019 Jun;25(6):968-976. doi: 10.1038/s41591-019-0458-7. Epub 2019 Jun 6.
9
Exosomes: composition, biogenesis, and mechanisms in cancer metastasis and drug resistance.外泌体:在癌症转移和耐药中的组成、发生机制和作用。
Mol Cancer. 2019 Apr 2;18(1):75. doi: 10.1186/s12943-019-0991-5.
10
The microbiome, cancer, and cancer therapy.微生物组、癌症与癌症治疗。
Nat Med. 2019 Mar;25(3):377-388. doi: 10.1038/s41591-019-0377-7. Epub 2019 Mar 6.